Global Nuclear Imaging Market Industry Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The global nuclear imaging market comprises PET scanners, SPECT systems, and associated radiopharmaceuticals used for functional imaging in oncology, cardiology, neurology, and other clinical areas. The market was valued at approximately $5.86 billion in 2025 and is expected to reach around $9.2-9.5 billion by the early 2030s at a CAGR of roughly 5.96%, reflecting sustained demand for precision diagnostic tools.

• •Primary modalities include PET and SPECT scanners, with PET holding a larger and faster-growing market share.
• •Radiopharmaceuticals represent a significant and complementary segment alongside imaging hardware.
• •Applications span oncology, cardiology, neurology, and emerging theranostic (diagnostic plus therapeutic) uses.

The rising global incidence of cancer and cardiovascular diseases is a primary driver of nuclear imaging demand, as these modalities provide critical functional information for diagnosis and treatment planning. An aging global population further amplifies demand, given the higher prevalence of chronic conditions among elderly patients. Continuous innovation in equipment, such as digital PET/CT, AI-assisted image reconstruction, and theranostic isotope pairs, is expanding clinical utility and market adoption.

• •Increasing cancer and cardiovascular disease prevalence globally drives demand for early, precise diagnostic imaging.
• •Growing geriatric populations significantly contribute to higher rates of chronic disease requiring nuclear imaging.
• •Technological advancements including digital detectors, hybrid imaging, and AI are improving diagnostic accuracy and workflow efficiency.

The market is segmented primarily by product type (PET scanners, SPECT scanners, and associated equipment), application (oncology, cardiology, neurology, and others), end-user (hospitals, diagnostic imaging centers, and research institutions), and geography. North America currently dominates the global market due to high healthcare spending, advanced infrastructure, and favorable reimbursement environments. Asia-Pacific is the fastest-growing region, propelled by rising healthcare investments, expanding middle-class populations, and growing awareness of advanced diagnostics in countries such as China, India, and Japan. Europe holds a significant share supported by strong research activity and established healthcare systems.

• •By product, PET scanners command a larger share than SPECT, though both remain clinically essential.
• •North America leads in market share, while Asia-Pacific is the highest-growth region.
• •Emerging markets in Latin America, the Middle East, and Africa are gradually adopting nuclear imaging as healthcare infrastructure improves.

What are the recent trends and outlook?

The theranostics approach, combining diagnostic imaging with targeted radionuclide therapy, is a defining trend reshaping the nuclear imaging market, creating new revenue streams and clinical applications, particularly in oncology. Integration of artificial intelligence for image reconstruction, quantification, and workflow optimization is accelerating adoption of next-generation systems. Over the 2025-early-2030s forecast horizon, the market is expected to sustain steady growth of approximately 5.96% annually, underpinned by broadening clinical indications, favorable reimbursement evolution, and continued investment in radiopharmaceutical innovation and supply-chain resilience.

• •Theranostics is emerging as a transformative trend, expanding nuclear imaging from diagnostics into precision therapy guidance.
• •AI and machine learning are increasingly embedded in scanner software for improved image quality and interpretation speed.
• •Supply-chain diversification for key radioisotopes is a growing focus to address periodic production and logistics constraints.